Kanekar Amar
Department of Health Studies, 200 Prospect Street, Denike 14 B, East Stroudsburg University of Pennsylvania, East Stroudsburg, PA 18301-2999, USA. Email:
J Clin Med Res. 2010 Mar 20;2(2):55-61. doi: 10.4021/jocmr2010.03.255w. Epub 2010 Mar 11.
Biomarkers in predicting the progression of HIV infected individuals to a state of HIV disease (AIDS) are studied over more than a decade. Use of surrogate markers in the past for tracking clinical progression of the disease was limited, as little knowledge existed about the disease. The aim of this review was to address various changes in biomarker related studies taking place over the last five years, especially the trend towards use of newer biomarkers and experimentation with novel molecules in a quest for halting HIV disease progression. An open search of PUBMED database was made with search key words such as Biomarkers and AIDS (Acquired Immunodeficiency Syndrome).The following were the inclusion criteria for articles: a) all articles published in English language, b) years of publication between 2002-2008 and c) articles limited to adult population. This yielded a total of 417 articles. The criteria used for further judging these studies considered a) type of research design, b) number of biomarkers studied, c) validity of the biomarkers, d) techniques to assess the biomarkers and the impact of the studies in furthering biomarker research, e) sample size for the studies and f) article title or abstracts having the following key words biomarker or biomarkers and predict progression to AIDS. A total of 27 abstracts were reviewed and 12 studies met the above criteria. These 12 different studies consisted of three reviews, four cohort designs, three cross-sectional designs, one each of an observational, and an in-vitro design. The various biomarkers emerging as a results were primarily a mix of viral, neural, immunological, HLA (human leukocyte antigen) markers along with lymphocyte counts. Although there have been quite a few advancements in biomarker-related studies, majority of the novel biomarkers discovered need to be further evaluated and replicated in bigger, long-term efficacy trials. Efforts should also be made to discover newer genetic markers of disease progression. Biomarker feedback, a new concept, can be utilized in future studies addressing prevention of HIV infection or halting disease progression.
Biomarkers; Progression; Designs; HIV; AIDS; Validity.
在超过十年的时间里,人们一直在研究用于预测HIV感染者发展至HIV疾病(艾滋病)状态的生物标志物。过去使用替代标志物来追踪疾病的临床进展存在局限性,因为当时对该疾病的了解很少。本综述的目的是探讨过去五年中生物标志物相关研究发生的各种变化,特别是使用更新的生物标志物以及试验新型分子以阻止HIV疾病进展的趋势。使用诸如“生物标志物”和“艾滋病(获得性免疫缺陷综合征)”等搜索关键词对PUBMED数据库进行了公开搜索。文章的纳入标准如下:a)所有以英文发表的文章,b)2002年至2008年期间发表的文章,c)仅限于成年人群的文章。这总共产生了417篇文章。用于进一步评判这些研究的标准考虑了:a)研究设计类型,b)所研究的生物标志物数量,c)生物标志物的有效性,d)评估生物标志物的技术以及这些研究对推进生物标志物研究的影响,e)研究的样本量,f)文章标题或摘要中包含以下关键词“生物标志物”或“生物标志物”以及“预测发展至艾滋病”。总共审查了27篇摘要,12项研究符合上述标准。这12项不同的研究包括三篇综述、四项队列设计、三项横断面设计、一项观察性设计和一项体外设计。作为研究结果出现的各种生物标志物主要是病毒、神经、免疫、HLA(人类白细胞抗原)标志物以及淋巴细胞计数的组合。尽管在生物标志物相关研究方面已经取得了不少进展,但发现的大多数新型生物标志物需要在更大规模的长期疗效试验中进一步评估和验证。还应努力发现疾病进展的更新的遗传标志物。生物标志物反馈这一新概念可用于未来涉及预防HIV感染或阻止疾病进展的研究。
生物标志物;进展;设计;HIV;艾滋病;有效性。